Related Experiment Videos
Tackling Challenging Data Integrity Topics in 2020: Update on Good Clinical Practice Perspectives from the US FDA and
Ni A Khin1, Cheryl Grandinetti1, Hayley Dixey2
1Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Clinical Pharmacology and Therapeutics
|August 6, 2021
Summary
Regulators are enhancing global clinical trial oversight by focusing on data quality, protocol deviations, and electronic data. This ensures Good Clinical Practice (GCP) compliance and data integrity, especially post-COVID-19.
Area of Science:
- Regulatory Science
- Clinical Trial Management
- Data Integrity
Background:
- Globalization necessitates increased regulatory collaboration for clinical trial oversight.
- Ensuring data quality in novel trial designs presents significant challenges.
- The 2020 joint symposium highlighted key areas for regulatory focus.
Purpose of the Study:
- To summarize US Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency (MHRA) perspectives on clinical trial conduct.
- To address challenges in data quality, protocol deviations, and electronic data use.
- To discuss the impact of COVID-19 on clinical trials and future system adaptability.
Main Methods:
- Review of perspectives from the 2020 joint FDA/MHRA Good Clinical Practice (GCP) symposium.
- Analysis of key topics including data quality, protocol deviations, sponsor oversight, and electronic source data.
- Inclusion of case examples and discussion of real-world data applications.
Main Results:
- Agencies emphasize rigorous management of protocol deviations and robust sponsor oversight.
- Electronic source data, including electronic health records, are crucial for data integrity.
- Real-world data presents opportunities and considerations for regulatory decision-making.
- The COVID-19 pandemic highlighted the need for resilient and adaptable clinical trial systems.
Conclusions:
- Enhanced collaboration and focus on specific operational aspects are vital for global clinical trial integrity.
- Adaptable systems and adherence to Good Clinical Practice (GCP) are essential for maintaining data integrity.
- Future clinical trial oversight must address novel designs, electronic data, and pandemic preparedness.